We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01538433
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : August 19, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a survey of factors which affect a pathologically defined early or delayed diagnosis of IgA nephropathy in Guangdong General Hospital, Guangzhou, China. An early or delayed diagnosis of IgA nephropathy is pathologically defined using the recently published Oxford classification of IgA nephropathy. The factors to be surveyed include health examination including urine test, socioeconomic status of patients including education,etc.

Condition or disease
IgA Nephropathy

Study Design

Study Type : Observational
Actual Enrollment : 603 participants
Time Perspective: Retrospective
Official Title: A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy: an Observational Study
Study Start Date : February 2012
Primary Completion Date : December 2012
Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
biopsy-proven IgA nephropathy


Outcome Measures

Primary Outcome Measures :
  1. Factors potentially affecting an early or delayed diagnosis of IgA Nephropathy [ Time Frame: Before the biopsy ]

Secondary Outcome Measures :
  1. Glomerular filtration rate(GFR) decline rate or reaching end-stage renal disease (ESRD) or doubling of serum creatinine [ Time Frame: after the biopsy ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The consecutive biopsy-proven IgAN patients in Guangdong General Hospital, Guangzhou,China
Criteria

Inclusion Criteria:

  • biopsy-proven IgA Nephropathy patients in Guangdong General Hospital, Guangzhou,China
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538433


Locations
China, Guangdong
Nephrology Department,Guangdong General Hospital
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
Guangdong General Hospital
Investigators
Principal Investigator: Wei Shi, MD, PhD Guangdong General Hospital
More Information

Responsible Party: Wei Shi, Prof., Guangdong General Hospital
ClinicalTrials.gov Identifier: NCT01538433     History of Changes
Other Study ID Numbers: GGH201107
First Posted: February 24, 2012    Key Record Dates
Last Update Posted: August 19, 2015
Last Verified: August 2013

Keywords provided by Wei Shi, Guangdong General Hospital:
diagnosis
IgA nephropathy

Additional relevant MeSH terms:
Kidney Diseases
Glomerulonephritis, IGA
Urologic Diseases
Glomerulonephritis
Nephritis
Autoimmune Diseases
Immune System Diseases